COVID-19: Pfizer-BioNTech vaccine 100% efficient in 12 to 15-year-olds, say firms
Part 3 trials carried out on 2,260 adolescents in the US “demonstrated one hundred pc efficacy and sturdy antibody responses”, the businesses mentioned in an announcement.
“We plan to submit these information to (US regulator) FDA as a proposed modification to our Emergency Use Authorisation within the coming weeks and to different regulators all over the world, with the hope of beginning to vaccinate this age group earlier than the beginning of the following college 12 months,” mentioned Pfizer chief government Albert Bourla.
Chief government of German firm BioNTech mentioned the outcomes displaying excessive safety for teenagers have been “very encouraging given the tendencies now we have seen in current weeks concerning the unfold of the B.1.1.7 UK variant”.
The BioNTech/Pfizer shot is predicated on novel mRNA know-how and was the primary COVID-19 vaccine to be permitted within the West late final 12 months.
Each the US and the European Union have permitted its use for individuals aged 16 and above.
Since then, it has been utilized in hundreds of thousands of adults in additional than 65 nations.
An actual-world research involving 1.2 million individuals in Israel discovered it to be 94 % efficient.
With the world scrambling to inoculate, BioNTech mentioned Tuesday it was on observe to fabricate 2.5 billion doses of its vaccine this 12 months.
The upper output was pushed by the current launch of a brand new manufacturing website within the German metropolis of Marburg, which is now one of many world’s largest mRNA vaccine manufacturing crops, it mentioned.
The vaccine can also be being produced at a Pfizer plant in Belgium and at three websites in the US.
BioNTech mentioned improved effectivity and new cooperation agreements with exterior companions had additionally helped raise its vaccine goal, as had the regulatory nod permitting vaccinators to extract six as an alternative of simply 5 doses from a single BioNTech/Pfizer vial.
BioNTech and Pfizer final week started research of the jab on kids, with the primary group of five-to-11-year-olds getting the vaccine.
A youthful cohort of two-to-five-year-olds is anticipated to get their first dose subsequent week within the research which may even cowl kids as younger as six months outdated.
#COVID19 #PfizerBioNTech #vaccine #efficient #15yearolds #firms